Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase 3 trials
from Future Medicine
This study aimed to benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan–Meier curves.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063